These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 29621528)
21. Anti-human erythrocyte antibodies in horse-derived antivenoms used in the treatment of snakebite envenomations. León G; Rodríguez MA; Rucavado A; Lomonte B; Gutiérrez JM Biologicals; 2007 Mar; 35(1):5-11. PubMed ID: 16490363 [TBL] [Abstract][Full Text] [Related]
22. Clinical studies of the effectiveness and safety of antivenoms. Williams DJ; Habib AG; Warrell DA Toxicon; 2018 Aug; 150():1-10. PubMed ID: 29746978 [TBL] [Abstract][Full Text] [Related]
25. Cross-neutralisation of Australian brown and tiger snake venoms with commercial antivenoms: Cross-reactivity or antivenom mixtures? O'Leary MA; Schneider JJ; Krishnan BP; Lavis C; McKendry A; Ong LK; Isbister GK Toxicon; 2007 Aug; 50(2):206-13. PubMed ID: 17467763 [TBL] [Abstract][Full Text] [Related]
26. [Hematologic values and serum enzymes in horses inoculated with snake venoms for the production of antivenins in Costa Rica]. Estrada R; Chaves F; Robles A; Rojas E; Segura E; Gutiérrez JM Rev Biol Trop; 1992 Apr; 40(1):95-9. PubMed ID: 1297173 [TBL] [Abstract][Full Text] [Related]
27. Integrating Engineering, Manufacturing, and Regulatory Considerations in the Development of Novel Antivenoms. Laustsen AH; Dorrestijn N Toxins (Basel); 2018 Jul; 10(8):. PubMed ID: 30065185 [TBL] [Abstract][Full Text] [Related]
28. A study on the use of caprylic acid and ammonium sulfate in combination for the fractionation of equine antivenom F(ab')(2). Simsiriwong P; Eursakun S; Ratanabanangkoon K Biologicals; 2012 Sep; 40(5):338-44. PubMed ID: 22704919 [TBL] [Abstract][Full Text] [Related]
29. Cross neutralization of dangerous snake venoms from Africa and the Middle East using the VACSERA polyvalent antivenom. Egyptian Organization for Biological Products & Vaccines. Seddik SS; Wanas S; Helmy MH; Hashem M J Nat Toxins; 2002 Dec; 11(4):329-35. PubMed ID: 12503876 [TBL] [Abstract][Full Text] [Related]
30. A new ELISA for determination of potency in snake antivenoms. Rial A; Morais V; Rossi S; Massaldi H Toxicon; 2006 Sep; 48(4):462-6. PubMed ID: 16893558 [TBL] [Abstract][Full Text] [Related]
31. Incidence of snakebites in Kaltungo, Gombe State and the efficacy of a new highly purified monovalent antivenom in treating snakebite patients from January 2009 to December 2010. Ademola-Majekodunmi FO; Oyediran FO; Abubakar SB Bull Soc Pathol Exot; 2012 Aug; 105(3):175-8. PubMed ID: 22851309 [TBL] [Abstract][Full Text] [Related]
32. Cross-Neutralisation of In Vitro Neurotoxicity of Asian and Australian Snake Neurotoxins and Venoms by Different Antivenoms. Silva A; Hodgson WC; Isbister GK Toxins (Basel); 2016 Oct; 8(10):. PubMed ID: 27763543 [TBL] [Abstract][Full Text] [Related]
33. Preclinical Evaluation of the Efficacy of Antivenoms for Snakebite Envenoming: State-of-the-Art and Challenges Ahead. Gutiérrez JM; Solano G; Pla D; Herrera M; Segura Á; Vargas M; Villalta M; Sánchez A; Sanz L; Lomonte B; León G; Calvete JJ Toxins (Basel); 2017 May; 9(5):. PubMed ID: 28505100 [TBL] [Abstract][Full Text] [Related]
34. Comparison of Montanide adjuvants, IMS 3012 (Nanoparticle), ISA 206 and ISA 35 (Emulsion based) along with incomplete Freund's adjuvant for hyperimmunization of equines used for production of polyvalent snake antivenom. Waghmare A; Deopurkar RL; Salvi N; Khadilkar M; Kalolikar M; Gade SK Vaccine; 2009 Feb; 27(7):1067-72. PubMed ID: 19100805 [TBL] [Abstract][Full Text] [Related]
35. Comparison of the effect of Crotalus simus and Crotalus durissus ruruima venoms on the equine antibody response towards Bothrops asper venom: implications for the production of polyspecific snake antivenoms. Dos-Santos MC; Arroyo C; Solano S; Herrera M; Villalta M; Segura A; Estrada R; Gutiérrez JM; León G Toxicon; 2011 Feb; 57(2):237-43. PubMed ID: 21130107 [TBL] [Abstract][Full Text] [Related]
36. Critical aspects on traditional antivenom production processes and their optimization by factorial analysis. Zurbano BN; Tavarone E; Viacava BG; Dokmetjian JC; Cascone O; Fingermann M Biologicals; 2020 Nov; 68():65-73. PubMed ID: 32912811 [TBL] [Abstract][Full Text] [Related]
37. Safety of snake antivenom immunoglobulins: efficacy of viral inactivation in a complete downstream process. Caricati CP; Oliveira-Nascimento L; Yoshida JT; Caricati AT; Raw I; Stephano MA Biotechnol Prog; 2013; 29(4):972-9. PubMed ID: 23804299 [TBL] [Abstract][Full Text] [Related]
38. Snakebite envenoming from a global perspective: Towards an integrated approach. Gutiérrez JM; Williams D; Fan HW; Warrell DA Toxicon; 2010 Dec; 56(7):1223-35. PubMed ID: 19951718 [TBL] [Abstract][Full Text] [Related]
39. Reducing the impact of snakebite envenoming in Latin America and the Caribbean: achievements and challenges ahead. Gutiérrez JM Trans R Soc Trop Med Hyg; 2014 Sep; 108(9):530-7. PubMed ID: 25096295 [TBL] [Abstract][Full Text] [Related]
40. Anticomplementary activity of equine whole IgG antivenoms: comparison of three fractionation protocols. León G; Lomonte B; Gutiérrez JM Toxicon; 2005 Jan; 45(1):123-8. PubMed ID: 15581691 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]